Navigation Links
Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
Date:5/30/2008

am includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at the ASGT meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
2. Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R)
3. Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent
4. Oncolytics Biotech Inc. Collaborators to Present Phase II Sarcoma Trial Results at ASCO Annual Meeting
5. Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
7. Oncolytics Biotech Inc. Announces Details of 2008 Annual Shareholder Meeting
8. Oncolytics Biotech Inc. Announces 2008 First Quarter Results
9. Oncolytics Biotech Inc. Announces Journal of Immunology Publication on Reovirus Activation of Dendritic Cells
10. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
11. Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Multiple Myeloma at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Riordan-McKenna Institute ... announced today that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed by ... otherwise non-healing surgical knee wound. , The case involved a 78-year-old male, who ...
(Date:8/28/2015)... ... ... launch of FireflySci Inc. (FFS) in early 2015, the company continues to shake up the ... Fonz in a lab coat and Large Marge have been posted on the company’s Facebook ... FireflySci is proud to be the only cuvette manufacturer is the world that has an ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas ... investment firms and animal health companies to hear from animal health companies with ... have also received licensing agreements or distribution contracts. This meeting is one ...
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , ... problems, is pleased to announce their ranking as one of the top 5000 companies ... fastest-growing private companies across the nation. , “It is truly an honor to be ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3
... Receive Funding, From Allied Minds to Commercialize Novel Technology for the ... ... Aliquots, BOSTON, July 2 Allied Minds, a pre-seed investment,corporation ... Development, and Northeastern,University announce the creation of CryoXtract Instruments, LLC, a ...
... levels as a possible ... predictor of clinical activity -, TORONTO, ... ("Lorus" or the "Corporation"), a biopharmaceutical company,specializing in the research ... cancer, today announced publication by,an Ohio State University (OSU) clinical ...
... Microfluidic Systems Inc.,(MFSI) announced today that it has ... of Microfluidic - Bioagent Autonomous Networked Detector,(M-BAND). This ... funded phases by the DHS,Science and Technology Directorate ... allow for low-volume production of automated,systems for extended ...
Cached Biology Technology:Investment Firm Allied Minds to Commercialize New Frozen Aliquotter Technology with Two Local Major Universities. 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 3Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 4Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 5Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems 2Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems 3
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
(Date:8/12/2015)... , Aug. 12, 2015  New research unveiled ... attack Android phones to steal users, fingerprints. Information ... availability of fingerprint scanners on mobile devices, making ... To secure biometrics on mobile devices, HYPR Corp. ... these convenient authentication systems with strong cryptographic security. ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, ... expected revenues in 2015 that relate to sales of FPC1155 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... smartphone manufacturer in China and ... 155 for Z1 , ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... the form of tiny grains resembling powder, which is ... from the European Synchrotron Radiation Facility (ESRF) and the ... the synchrotron to determine the structure of microcrystal grains ... a thousand on the size of the analysable samples, ...
... may help reduce the risk of pancreatic cancer, says ... found naturally in apples and onions, has been identified ... and reducing the risk of pancreatic cancer. Although ... smokers who consumed foods rich in flavonols had a ...
... Children,s Research Hospital settled a century-old debate on the ... and capillaries critical to various essential housekeeping functions in ... development of new therapies for lymphatic system disorders, the ... various mouse models to demonstrate that the lymphatic vasculature ...
Cached Biology News:Unveiling the structure of microcrystals 2Naturally-occurring apple compounds reduce risk of pancreatic cancer 2St. Jude settles century-old debate on origin of mammalian network of lymphatic vessels 2St. Jude settles century-old debate on origin of mammalian network of lymphatic vessels 3